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Purpose: Cigarette smoking and advanced age are well known as risk factors for chronic 
obstructive pulmonary disease (COPD), and nutritional abnormalities are important in patients 
with COPD. However, little is known about the nutritional status in non-COPD aging men with 
smoking history. We therefore investigated whether reduced lung function is associated with 
lower blood markers of nutritional status in those men.
Subjects and methods: This association was examined in a cross-sectional study of 65 
Japanese male current or former smokers aged 50 to 80 years: 48 without COPD (non-COPD 
group), divided into tertiles according to forced expiratory volume in one second as percent of 
forced vital capacity (FEV1/FVC), and 17 with COPD (COPD group).
Results: After adjustment for potential confounders, lower FEV1/FVC was significantly associ-
ated with lower red blood cell count (RBCc), hemoglobin, and total protein (TP); not with total 
energy intake. The difference in adjusted RBCc and TP among the non-COPD group tertiles was 
greater than that between the bottom tertile in the non-COPD group and the COPD group.
Conclusion: In non-COPD aging men with smoking history, trends toward reduced nutritional 
status and anemia may independently emerge in blood components along with decreased lung 
function even before COPD onset.
Keywords: anemia, chronic obstructive pulmonary disease, lung function, nutritional assess-
ment, nutritional status, smoking
Introduction
The prevalence of chronic obstructive pulmonary disease (COPD) is increasing with 
the aging of society.1,2 Cigarette smoking and advanced age are risk factors for COPD,3 
which not only decreases individual quality of life (QOL),4 but it also imposes a high 
burden of medical cost on the economy.1 Although the Global Initiative for Chronic 
Obstructive Lung Disease defines COPD as a preventable and treatable disease,3 
prevention is obviously much more important than treatment.
COPD is now recognized as a systemic disease.5 One of the systemic effects of COPD 
is the presence of nutritional abnormalities that causes body weight loss.5 Approximately 
50% of patients with severe COPD and 10% to 15% of those in the mild to moderate stage 
suffer body weight loss, possibly due to hypermetabolism.6 Decreases in body weight,7 
body mass index (BMI),8,9 and fat-free mass index9 have been reported to be associ-
ated with mortality in patients with COPD. In this context, many clinical studies have 
investigated the efficacy of nutritional support for patients with COPD, which, however, 
remains controversial. A meta-analysis by Ferreira et al indicated that nutritional support 
had no significant effect on anthropometric measures in patients with stable COPD.10 
This suggests that nutritional support for COPD patients to maintain healthy body International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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weight and composition is difficult. Moreover, COPD patients 
tend to have nutrition-related comorbidities such as diabetes 
and anemia,11 implying that patients with COPD likely have 
impaired metabolism or nutritional abnormalities. However, 
little is known about the association between lung function and 
nutritional status in those with risk factors for COPD, such as 
cigarette smoking and advanced age, but not falling under the 
category of COPD. Knowledge of this association is expected 
to be useful in the prevention of COPD.
In the present study, we tested the hypothesis that reduced 
lung function is associated with lower blood markers of 
nutritional status in non-COPD aging men with smoking 
history. In addition to an urgent need to prevent COPD, the 
fact that the cut-off point for COPD – forced expiratory vol-
ume in one second (FEV1) as percent of forced vital capacity 
(FVC) (FEV1/FVC) ,70% – has been used for pragmatic 
  simplicity12 without adequate medical evidence to support 
it13 seems to justify the necessity of the present study.
Subjects and methods
Study design
This cross-sectional study examined the association between 
lung function and blood markers of nutritional status in non-
COPD aging men with smoking history. Each eligible subject 
was asked to visit Okayama University Hospital Misasa 
Medical Center three times during the study. At the first 
visit, written informed consent was obtained; at the second 
visit, anthropometric measurements, blood sampling, and 
spirometry testing were conducted, followed by distribution 
of in-home, self-administered questionnaires on diet and 
lifestyle; and at the third visit, the completed questionnaires 
were collected and detailed interviews carried out by a 
registered dietician about their answers. The protocol of the 
present study was approved by the Ethics Committee of the 
Graduate School of Medicine, Dentistry and Pharmaceutical 
Sciences, Okayama University.
Subjects
Male current or former smokers aged 50 to 80 years were 
recruited in one of the following two ways: recruitment of 
COPD outpatients at Okayama University Hospital Misasa 
Medical Center or recruitment of those who had never been 
diagnosed with COPD and participated in a health promo-
tion program in a rural town in Tottori Prefecture, located 
in the western part of Japan. The exclusion criteria were: 
1) those who had been given dietary advice by medical staff 
(eg, physician or registered dietician) and confirmed that 
they were in compliance with the advice; 2) those taking 
drugs for hyperlipidemia, hyperglycemia, or diabetes; and 3) 
those who had suffered from a COPD exacerbation within 
the previous month.
Anthropometric, blood, and lung function 
measurements
At the second visit, each subject arrived at Okayama   University 
Hospital Misasa Medical Center between 08:30 and 10:00 
AM after overnight fasting. After measurements of height and 
abdominal circumference at the level of the umbilicus, body 
weight, BMI, and percent of body muscle were measured with 
a body composition analyser (DF860K, Yamato Scale Co., 
Ltd., Akashi, Hyogo, Japan) using the bioelectrical imped-
ance analysis method. Then, fasting blood was drawn from an 
antecubital vein in a sitting position for determining red blood 
cell count (RBCc), white blood cell count (WBCc), and levels 
of hemoglobin (Hb), hematocrit, total protein (TP), albumin, 
triglyceride, total cholesterol (TC), LDL-cholesterol (LDL-c), 
HDL-cholesterol (HDL-c), glucose, and HbA1c. The concen-
trations of the blood components listed above were measured 
using automatic analysers: XT-2000i (Sysmex America Inc., 
Mundelein, IL, USA) for RBCc, WBCc, Hb, and hematocrit; 
and Dimension® Xpand® (Siemens Healthcare Diagnostics 
Inc., Deerfield, IL, USA) for TP, albumin, triglyceride, TC, 
LDL-c, HDL-c, glucose, and HbA1c. Anthropometric mea-
surements and blood sampling were conducted by nurses. 
After blood sampling, spirometry testing was performed by 
a well-trained clinical technologist to assess FEV1/FVC and 
predicted forced expiratory volume in one second (FEV1% 
pred) according to the COPD guidelines of The Japan Respi-
ratory Society 2004.14 Subjects never before diagnosed with 
COPD underwent spirometry testing without a bronchodilator. 
Both the subjects with FEV1/FVC , 70% at the first test and 
COPD outpatients were asked to inhale 200 µg of salbutamol 
according to pharmacists’ instructions to avoid the effects 
of airway reversibility; 30 min after inhalation, spirometry 
testing was performed. Those with FEV1/FVC , 70% after 
bronchodilator administration were diagnosed with COPD. For 
subjects who inhaled salbutamol, post-bronchodilator values 
were used for data analysis.
Dietary assessment
Food and nutrient consumption was calculated using Excel 
Eiyo-kun FFQg software (version 2.0; Kenpakusha, Tokyo, 
Japan), a semiquantitative food frequency questionnaire 
based on the fifth revised and enlarged edition of the   Standard 
Tables of Food Composition in Japan. The respondents 
were asked about their usual dietary intake per week for International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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the previous month. Dietary interviews were conducted by 
registered dieticians using food models in order to increase 
the precision of the dietary intake estimate.
Lifestyle questionnaire
In the lifestyle questionnaire, subjects were asked about their 
medical history, medication use, smoking status, pack-years, 
and history of occupational dust exposure. To estimate pack-
years as precisely as possible, original graph paper sheets 
(95 × 140 mm) were prepared with the X-axis indicating 
age (10 to 85 years, at 5-year intervals) and the Y-axis indi-
cating the number of cigarettes smoked per day at each age 
(0 to 100 cigarettes, at intervals of 10 cigarettes). During the 
interview, subjects were asked about their graphs, and where 
necessary, age and the number of cigarettes were corrected. 
Then, pack-years were calculated from the graph using the 
trapezoidal method, and the duration of the current period 
of smoking cessation was obtained.
Statistical analysis
First, subjects were assigned to the COPD group (the refer-
ence group) or the non-COPD group, and the non-COPD 
group was then divided into groups according to FEV1/FVC 
results so that each group contained approximately the same 
number of subjects as the COPD group. The subjects’ charac-
teristics are presented as means ± standard deviation (SD) or 
percent. Values of blood test results and dietary intake in each 
subject group were expressed as adjusted means or geometric 
means and 95% confidence intervals, using analysis of covari-
ance (ANCOVA). Tests for linear trend across subject groups 
were performed by treating FEV1/FVC as a continuous vari-
able in multiple linear regression analyses. In ANCOVAs and 
multiple linear regression analyses, the following potential 
confounders were considered and included: age, BMI, percent 
of body muscle, total energy intake (kcal⋅day−1), pack-years, 
pack-years squared, current duration of smoking cessation 
(years), and history of occupational dust exposure (,1 year 
or $1 year). Variables that showed an extremely skewed dis-
tribution were transformed to natural logarithms (ln) (ln(X) 
or ln(X + 1)) for data analysis and then back-transformed to 
the original values. Statistical analysis was performed using 
SPSS version 16.0 J for Windows (SPSS Inc., Chicago, IL, 
USA), and a P-value ,0.05 (two-sided) was considered 
statistically significant.
Results
Written informed consent was obtained from 74 men. Of 
these, 3 dropped out, and 6 were excluded because of their 
healthier diet as advised by the medical staff (n = 5), and 
drinking juice just before blood drawing (n = 1). Therefore, 
65 subjects were included in the study (Figure 1).
Of these subjects, 17 were in the COPD group and 48 were 
in the non-COPD group. The distribution of the disease sever-
ity in the COPD group was as follows: 3 men with mild; 9 
with moderate; 4 with severe; and 1 with very severe disease. 
The non-COPD group was divided into tertiles (non-T3, top; 
non-T2, middle; non-T1, bottom tertile) according to FEV1/
FVC level for data analysis (Table 1).
Table 2 describes each group’s characteristics. The sub-
jects with lower FEV1/FVC tended to be older and to have 
lower height, weight, and BMI. The COPD group apparently 
had lower body muscle and total energy intake. The non-T1 
and COPD groups had a greater number of pack-years and 
longer histories of occupational dust exposure than the non-
T3 and non-T2 groups.
Table 3 shows the blood results for each group adjusted 
for potential confounders. Lower FEV1/FVC was significantly 
associated with lower RBCc, Hb, hematocrit, and TP, which 
are markers of anemia and nutritional status, in all adjusted 
models. RBCc and TP decreased by approximately 5% to 
6% between non-T3 and non-T1; this difference was larger 
than that observed between the non-T1 and COPD groups. 
Albumin showed a similar trend to RBCc and TP, but it was 
not statistically significant after adjustment for all potential 
confounders, including smoking variables and history of 
occupational dust exposure. In relation to fat metabolism, 
LDL-c was significantly lower with decreased FEV1/FVC in 
all adjusted models. There was a similar decreasing trend for 
TC, but it was not statistically significant after adjustment for 
age, BMI, percent of body muscle, and total energy intake. 
FEV1/FVC showed no association with glucose and HbA1c, 
which were similar across subject groups.
Table 4 shows the adjusted dietary intake for each group. 
FEV1/FVC was not associated with intake of total energy, 
protein, fat, or carbohydrate. However, iron intake tended to 
increase as FEV1/FVC decreases after adjustment for age, 
BMI, percent of body muscle, and energy intake. More-
over, the inverse association of FEV1/FVC with iron intake 
remained strong after further adjustment for smoking vari-
ables and history of occupational dust exposure. Although 
cholesterol intake showed a similar trend to that of iron, it 
was not statistically significant.
Discussion
The present study investigated a potential association between 
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current or former smokers. This study was unique in that non-
COPD subjects were categorized into three groups based on 
FEV1/FVC tertiles. In contrast, most previous studies in this 
field simply compared the COPD group with the non-COPD 
group without further dividing the subjects with non-COPD 
into groups. COPD is now defined as a preventable disease;3 
therefore, from the perspective of prevention, it is important 
to focus on those with risk factors such as smoking history 
and advanced age but who do not fulfil the COPD diagnostic 
criteria, especially men with an FEV1/FVC close to 70%.
Our main results were as follows: (1) lower FEV1/FVC 
was linearly associated with lower RBCc, Hb, hematocrit, TP, 
and LDL-c after adjustments for all potential confounders; 
(2) FEV1/FVC was not associated with intake of total energy, 
58 community-dwelling men
never diagnosed with COPD
16 COPD outpatients
3 excluded
– Dropped out (n = 3)
Anthropometric and blood measurements
58 underwent spirometry 
without bronchodilator
FEV1/FVC
Dietary intake and lifestyle questionnaire, 
followed by personal interview
<70%
(n = 6) ≥70%
(n = 52)
74 eligible subjects
1 excluded from 
analysis
– Healthier diet as 
advised by the 
medical staff (n = 1)
Non-COPD group (n = 48)
5 excluded from 
analysis
– Healthier diet as 
advised by the 
medical staff (n = 4)
– Drinking juice just 
before blood  
sampling (n = 1) 
19 underwent spirometry 
with bronchodilator
FEV1/FVC
≥70%
(n = 1) <70%
(n = 18)
COPD group (n = 17)
– 13 COPD outpatients
– 4 community-dwelling men  
newly diagnosed with COPD
Non-T2
(n = 16)
Non-T1
(n = 16)
Non-T3
(n = 16)
Figure 1 Subject flow diagram.
Abbreviations: COPD, chronic obstructive pulmonary disease; FeV1/FVC, forced expiratory volume in one second as percent of forced vital cavity; T, tertile.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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protein, fat, carbohydrate, or cholesterol. Together, these results 
support our hypothesis that reduced lung function is associated 
with reduced nutritional status in non-COPD aging men with 
smoking history. This suggests that in those men, trends toward 
reduced nutritional status and anemia may emerge indepen-
dently as changes in blood test results, along with decreased 
lung function, even before the onset of COPD.
TP and albumin are markers of nutritional status.15 In the 
present study, FEV1/FVC was linearly associated with TP in all 
adjusted models, and the decrease in adjusted TP between the 
non-T3 and non-T1 groups was larger than that between the 
non-T1 and COPD groups. Nevertheless, FEV1/FVC was not 
associated with adjusted intake of total energy and nutrients, 
except iron. To the best of our knowledge, this is the first study 
to report that decreasing degree of TP in non-COPD aging men 
with smoking history could be comparable to or greater than 
that in COPD patients. In contrast to TP, the association between 
albumin and FEV1/FVC was slight. One possible explanation 
for this is that albumin is pooled in the extravascular space and 
is then mobilized to the intravascular space as needed with its 
degradation rate decreasing, which allows a relatively constant 
blood level to be maintained.16–18
COPD has been reported to be associated with anemia,19,20 
which is causally related to dyspnoea, reduced exercise 
capacity,21 and health-related QOL.22 The mechanism of COPD 
is believed to be similar to that of other chronic diseases. In 
patients with chronic diseases, elevated levels of inflammatory 
cytokines could shorten RBC survival, impair mobilization 
or utilization of iron, and impair the marrow erythropoietic 
response.19,23 In the present study, lower FEV1/FVC was lin-
early associated with lower RBCc, Hb, and hematocrit after 
adjustments for all potential confounders. In contrast, FEV1/
FVC was inversely associated with adjusted iron intake; sub-
jects with a lower FEV1/FVC had a greater iron intake. These 
findings suggest that RBC dysregulation, in which impaired 
utilization of iron is implicated, could occur in male current 
or former smokers as FEV1/FVC decreases even before the 
onset of COPD. It has been shown that cigarette smoking alters 
iron homeostasis, greatly increases lung iron concentration, 
and generates oxidative stress and inflammation,24 which may 
increase the iron requirement. A meta-analysis by Gan et al 
indicated that WBCc may be a useful marker of systemic 
inflammation in COPD patients.25 Van Hoydonck et al reported 
that male current smokers and female current or former 
smokers had greater iron intake than male former smokers 
and female never smokers,   respectively.26 In the present study, 
WBCc and iron intake in the non-T1 and COPD groups were 
greater than those in the non-T3 and non-T2 groups, implying 
that there is an association between inflammation and iron 
requirement in male current or former smokers, even before 
Table 2 Subjects’ characteristics
Non-COPD group COPD 
group Non-T3 Non-T2 Non-T1
Subjects (n) 16 16 16 17
Age (yrs) 60 ± 6 60 ± 7 65 ± 6 70 ± 7
height (cm) 169 ± 7 169 ± 3 164 ± 5 165 ± 7
Weight (kg) 69 ± 10 63 ± 7 60 ± 9 60 ± 7
BMI (kg⋅m−2) 24.1 ± 2.2 22.2 ± 2.3 22.2 ± 2.8 22.1 ± 2.7
Body muscle (%) 32 ± 3 33 ± 2 32 ± 3 30 ± 5
Body fat (%) 24 ± 5 21 ± 6 20 ± 7 23 ± 7
Abdominal circumference (cm) 87 ± 6 83 ± 7 82 ± 9 84 ± 8
Total energy intake (kcal⋅d−1) 2137 ± 260 2148 ± 414 2206 ± 545 1927 ± 490
Smoking status
  Current smoker (n) 7 (44) 7 (44) 9 (56) 5 (29)
  Former smoker (n) 9 (56) 9 (56) 7 (44) 12 (71)
    Current duration of smoking cessation  
    in former smokers (yrs)
6.9 ± 5.3 14.4 ± 10.9 8.7 ± 6.7 10.8 ± 9.2
Pack-years 45 ± 13 32 ± 19 53 ± 18 52 ± 32
history of occupational dust exposure $1 year (n) 1 (6) 4 (25) 7 (44) 7 (41)
Notes: Data are presented as mean ± SD, n or n (%).
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; T, tertile.
Table 1 Classification of subjects according to FEV1/FVC
Subjects n FEV1/FVC %
Min to max Mean ± SD
non-COPD group
  non-T3 16 78.9 to 85.4 81.5 ± 2.4
  non-T2 16 73.5 to 78.7 75.7 ± 1.7
  non-T1 16 70.1 to 73.3 71.9 ± 1.1
COPD group 17 31.0 to 67.7 52.4 ± 11.0
Abbreviations: COPD, chronic obstructive pulmonary disease; FeV1/FVC, forced 
expiratory volume in one second as percent of forced vital cavity; T, tertile.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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Table 3 Association between FeV1/FVC and adjusted blood components
Non-COPD group COPD group  P-value¶
Non-T3  
(n = 16)
Non-T2  
(n = 16)
Non-T1  
(n = 16)
 
(n = 17)
Adj  
mean
95%  
CI
Adj  
mean
95%  
CI
Adj  
mean
95%  
CI
Adj  
mean
95%  
CI
rBC (106⋅µl−1) Model 1 4.94 4.77 to 5.10 4.81 4.65 to 4.98 4.64 4.48 to 4.80 4.52 4.36 to 4.69 ,0.001
Model 2 4.93 4.76 to 5.09 4.83 4.67 to 4.99 4.62 4.47 to 4.78 4.54 4.37 to 4.70 ,0.001
Model 3 4.96 4.79 to 5.13 4.80 4.63 to 4.97 4.64 4.48 to 4.80 4.52 4.35 to 4.69 ,0.001
WBC (103⋅µl−1) Model 1 5.77 4.92 to 6.61 5.39 4.54 to 6.23 6.63 5.81 to 7.45 6.69 5.82 to 7.56 0.075
Model 2 5.66 4.78 to 6.54 5.41 4.55 to 6.26 6.73 5.90 to 7.56 6.68 5.79 to 7.57 0.051
Model 3 5.66 4.77 to 6.55 5.54 4.65 to 6.43 6.68 5.83 to 7.52 6.60 5.72 to 7.48 0.081
hb (g⋅dl−1) Model 1 15.2 14.8 to 15.7 15.0 14.6 to 15.4 14.9 14.5 to 15.3 14.3 13.9 to 14.8 0.014
Model 2 15.2 14.8 to 15.7 15.0 14.6 to 15.5 14.9 14.5 to 15.3 14.3 13.9 to 14.8 0.013
Model 3 15.4 14.9 to 15.8 15.0 14.5 to 15.5 14.9 14.4 to 15.3 14.2 13.8 to 14.7 0.003
hematocrit (%) Model 1 46.7 45.4 to 47.9 46.2 44.9 to 47.4 45.7 44.5 to 46.9 44.0 42.7 to 45.3 0.008
Model 2 46.7 45.4 to 48.0 46.2 45.0 to 47.5 45.6 44.4 to 46.8 44.0 42.7 to 45.3 0.008
Model 3 47.1 45.7 to 48.4 46.2 44.9 to 47.5 45.5 44.3 to 46.8 43.8 42.5 to 45.1 0.002
TP (g⋅dl−1) Model 1 7.9 7.7 to 8.1 7.7 7.4 to 7.9 7.5 7.3 to 7.7 7.4 7.2 to 7.6 ,0.001
Model 2 7.9 7.7 to 8.1 7.7 7.5 to 7.9 7.5 7.3 to 7.7 7.4 7.1 to 7.6 ,0.001
Model 3 7.9 7.7 to 8.2 7.7 7.5 to 7.9 7.5 7.3 to 7.7 7.3 7.1 to 7.6 ,0.001
Albumin (g⋅dl−1)# Model 1 4.2 4.0 to 4.3 4.1 4.0 to 4.2 4.1 4.0 to 4.2 4.0 3.8 to 4.1 0.032
Model 2 4.2 4.0 to 4.3 4.1 4.0 to 4.2 4.1 3.9 to 4.2 4.0 3.8 to 4.1 0.036
Model 3 4.2 4.0 to 4.3 4.1 4.0 to 4.3 4.1 3.9 to 4.2 4.0 3.8 to 4.1 0.066
Trigryceride (mg⋅dl−1)# Model 1 154 122 to 195 108 85 to 137 120 96 to 151 115 90 to 147 0.139
Model 2 141 112 to 178 111 89 to 139 121 97 to 150 121 96 to 153 0.462
Model 3 143 114 to 180 112 89 to 140 121 97 to 150 119 95 to 149 0.366
TC (mg⋅dl−1) Model 1 219 204 to 235 205 190 to 221 190 175 to 206 198 182 to 214 0.040
Model 2 220 203 to 236 204 189 to 221 190 174 to 206 199 182 to 215 0.053
Model 3 220 203 to 238 208 190 to 225 187 171 to 203 198 181 to 215 0.045
LDL-c (mg⋅dl−1) Model 1 140 125 to 155 121 106 to 136 102 87 to 117 114 98 to 130 0.011
Model 2 139 123 to 155 121 106 to 137 102 87 to 118 114 98 to 130 0.021
Model 3 139 123 to 155 127 110 to 143 97 82 to 113 114 97 to 130 0.015
hDL-c (mg⋅dl−1) Model 1 49 44 to 55 56 50 to 62 58 53 to 64 52 46 to 58 0.379
Model 2 52 46 to 58 55 49 to 60 57 52 to 63 52 46 to 57 0.862
Model 3 52 46 to 58 53 47 to 59 58 53 to 64 52 46 to 58 0.749
glucose (mg⋅dl−1) Model 1 102 96 to 107 101 96 to 106 103 98 to 108 101 96 to 107 0.956
Model 2 100 95 to 106 102 97 to 107 104 99 to 109 101 96 to 107 0.637
Model 3 100 94 to 106 101 96  to 107 104 99 to 109 102 96 to 107 0.597
hbA1c (%)# Model 1 5.4 5.2 to 5.5 5.3 5.2 to 5.5 5.3 5.2 to 5.5 5.4 5.3 to 5.6 0.797
Model 2 5.4 5.2 to 5.5 5.3 5.2 to 5.5 5.3 5.2 to 5.5 5.4 5.2 to 5.6 0.718
Model 3 5.4 5.2 to 5.5 5.3 5.2 to 5.5 5.3 5.2 to 5.5 5.4 5.2 to 5.6 0.762
Notes: Model 1, adjusted for age; Model 2, adjusted for age, body mass index, percent of body muscle, and total energy intake; Model 3, adjusted for all variables in Model 2 plus 
pack-years, pack-years squared, current-duration of smoking cessation, and history of occupational dust exposure $1 year; #log transformed for data analysis to improve normality, 
and back transformed to present data; ¶test for linear trend across groups was performed by treating FeV1/FVC as a continuous variable in multiple linear regression analysis.
Abbreviations: Adj, adjusted; COPD, chronic obstructive pulmonary disease; CI, confidence interval; FEV1/FVC, forced expiratory volume in one second as percent of forced 
vital cavity; hb, hemoglobin; hDL-c, hDL-cholesterol; LDL-c, LDL-cholesterol; rBC, red blood cell; T, tertile; TC, total cholesterol; TP, total protein; WBC, white blood cell.
the onset of COPD. In the present study, the levels of anemia 
markers in each subject group were all within the normal 
range, which can be explained as follows: first, the prevalence 
of anemia is actually not very high, even in COPD patients. 
In a cross-sectional study by John et al,20 the prevalence of 
anemia in COPD patients was 13%, and that in a retrospective 
study by Cote et al21 was 17%. Second, three-fourths of the 
subjects in the present study were in the non-COPD group. 
Further studies focusing on associations between FEV1/FVC 
and serum iron, transferrin, ferritin, transferrin receptor, and 
inflammatory cytokines in male current or former smokers 
with non-COPD are needed.
Although several previous studies have reported an associa-
tion between lung function and diabetes,27 most used FEV1 or 
FVC, not FEV1/FVC, as markers of lung function, which seems 
to be insufficient to evaluate whether chronic airflow obstruction International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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Table 4 Association between FeV1/FVC and adjusted dietary intake
Non-COPD group COPD group  P-value¶
Non-T3  
(n = 16)
Non-T2  
(n = 16)
Non-T1  
(n = 16)
 
(n = 17)
Adj  
mean
95%  
CI
Adj  
mean
95%  
CI
Adj  
mean
95%  
CI
Adj  
mean
95%  
CI
Total energy (kcal⋅d−1) Model 1 2114 1884 to 2344 2123 1893 to 2354 2214 1991 to 2436 1965 1728 to 2203 0.561
Model 2 2081 1841 to 2321 2133 1899 to 2367 2225 1999 to 2450 1977 1737 to 2217 0.723
Model 3 2128 1879 to 2378 2154 1905 to 2403 2177 1940 to 2414 1957 1713 to 2202 0.416
Protein (g⋅d−1)# Model 1 66.8 59.0 to 75.6 66.2 58.4 to 75.0 74.2 65.9 to 83.7 65.6 57.7 to 74.6 0.835
Model 2 66.0 61.3 to 71.0 65.7 61.1 to 70.6 70.8 66.1 to 75.9 69.9 64.9 to 75.3 0.172
Model 3 65.8 61.0 to 71.1 64.6 59.9 to 69.8 71.9 66.8 to 77.3 70.1 65.0 to 75.6 0.137
Fat (g⋅d−1)# Model 1 55.9 47.1 to 66.4 54.8 46.1 to 65.1 53.1 45.0 to 62.8 50.4 42.2 to 60.2 0.422
Model 2 55.1 49.5 to 61.4 53.9 48.5 to 59.9 50.2 45.3 to 55.6 54.8 49.1 to 61.1 0.722
Model 3 54.9 48.9 to 61.5 55.4 49.4 to 62.1 49.2 44.1 to 54.8 54.7 48.9 to 61.3 0.674
Carbohydrate (g⋅d−1) Model 1 292.6 260.7 to 324.5 302.2 270.2 to 334.2 301.4 270.6 to 332.3 271.9 239.0 to 304.8 0.473
Model 2 290.6 272.5 to 308.8 300.7 283.0 to 318.4 288.0 270.8 to 305.1 287.9 269.5 to 306.2 0.668
Model 3 293.1 274.1 to 312.0 296.8 277.9 to 315.7 291.1 273.1 to 309.2 286.3 267.5 to 305.1 0.587
Cholestrol (mg⋅d−1)# Model 1 264 220 to 317 266 222 to 319 346 290 to 412 276 229 to 333 0.386
Model 2 257 221 to 298 265 229 to 306 330 287 to 380 298 256 to 346 0.072
Model 3 253 218 to 295 264 226 to 306 336 291 to 388 297 256 to 346 0.066
Iron (mg⋅d−1)# Model 1 6.8 5.9 to 7.8 7.4 6.4 to 8.6 8.3 7.3 to 9.6 7.1 6.2 to 8.3 0.402
Model 2 6.6 5.9 to 7.2 7.4 6.8 to 8.2 8.0 7.3 to 8.8 7.7 7.0 to 8.5 0.020
Model 3 6.5 5.9 to 7.2 7.2 6.5 to 8.0 8.2 7.5 to 9.0 7.8 7.0 to 8.6 0.009
Notes: Model 1, adjusted for age; Model 2, adjusted for age, body mass index, percent of body muscle, and total energy intake (except for analysis of total energy intake); 
Model 3, adjusted for all variables in Model 2 plus pack-years, pack-years squared, current-duration of smoking cessation, and history of occupational dust exposure $1 year; 
#log transformed for data analysis to improve normality, and back transformed to present data; ¶test for linear trend across groups was performed by treating FeV1/FVC as 
a continuous variable in multiple linear regression analysis.
Abbreviations: Adj, adjusted; CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV1/FVC, forced expiratory volume in one second as percent of 
forced vital cavity; T, tertile.
is related to glucose metabolism. In the present study, FEV1/
FVC was not associated with glucose or HbA1c, suggesting that 
chronic airflow obstruction is not independently associated with 
glucose control. The present result was consistent with that of 
a large prospective study by Ford et al,28 in which FEV1, FVC, 
and FEV1% pred were significantly negatively associated with 
the incidence of diabetes, whereas FEV1/FVC was not. In the 
present study, subjects who took drugs for hyperglycemia or 
diabetes were excluded so that medication use did not mask 
impaired glucose control, which may also result in the disas-
sociation of FEV1/FVC with glucose and HbA1c.
The present study had several limitations. First, we cannot 
completely rule out the possibility of chance due to relatively 
small sample size. In spite of the relatively small sample size, 
however, it was noted that lower FEV1/FVC was significantly 
associated with lower TP and Hb, and future studies are 
warranted to confirm these results in larger samples. Second, 
while it is essential to consider physical activity for nutritional 
assessment, the data on physical activity was not available in 
the present study; this may somewhat confound associations 
between FEV1/FVC and nutritional markers. Although it has 
been reported that men with COPD have elevated resting 
energy expenditure29,30 or daily activity energy expenditure,31,32 
most subjects had relatively high FEV1/FVC, and it is less 
likely that the present findings are fully explained by the resid-
ual confounding. Although it remains unknown whether energy 
expenditure tended to be elevated among men whose FEV1/
FVC fell close to 70%, future studies should aim to reduce 
the confounding due to physical activity by measuring resting 
energy expenditure and daily activity energy expenditure.
In summary, the present study shows that lower FEV1/
FVC is independently linearly associated with lower blood 
markers of nutritional status and anemia. The present results 
suggest that, in non-COPD aging men with smoking history, 
slight but significant trends toward reduced nutritional status 
and anemia may emerge along with decreased lung function 
even before the onset of COPD. Further studies are needed to 
examine the mechanism by which disease progression occurs 
in current or former smokers with non-COPD.
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